United States Patent 10,533,042: Claim-Level Appraisal and US Patent Landscape for MSC-to-Chondrocyte Differentiation Polypeptides

What does US 10,533,042 claim, in enforceable terms?

US 10,533,042 centers on a method for inducing differentiation of mesenchymal stem cells (MSCs) into chondrocytes by contacting MSCs with a specific polypeptide class defined through three tight constraints:

Sequence similarity gate
The polypeptide must have at least 95% amino acid sequence identity to a member selected from a defined set of sequences (your “TABLE 1” / “SEQ ID NO” set).
A single-position functional rule
The polypeptide must include a polar amino acid other than K or R at position 423 as determined relative to SEQ ID NO:1.
Functional requirement
The polypeptide must have chondrogenic activity.

These appear across claim structure as follows:

Claim 1 is the broadest independent claim and ties together identity threshold + position 423 rule + chondrogenic activity.
Claims 2-5 narrow/define the acceptable polypeptide sequences (depending on “selected from” vs “consists of” language).
Claims 6-8 narrow the residue at position 423 to Q or S.
Claims 9-10 add formulation/conjugation and fusion options (PEGylation; fusions to HSA/Fc/GST/MBP, etc.).
Claims 11-20 narrow to in vivo joint administration in humans, including arthritis types and extensive add-on therapy bundles (hyaluronic acid, iNOS inhibitor, vitamin D3, FGF18, BMP7, rusalatide, ASU, kartogenin, steroids, NSAIDs, calcitonin, surgery, and cartilage repair procedures).

How do claims 1-8 define a “particular” polypeptide space instead of a general chondrogenic factor?

The patent does not claim “any chondrogenic polypeptide.” It claims polypeptides constrained by:

95% identity to one of the enumerated sequences (large enough to tolerate variants, small enough to avoid broadness to unrelated proteins).
A specific amino acid property at one locus (position 423), anchored to SEQ ID NO:1, which is a classic method to capture variants that preserve function at a critical residue.
Chondrogenic activity, which is both a claim element and a litigation flashpoint (proof of activity is often contested, even when prior art suggests biological plausibility).

The locus rule is the sharpest blade in claim 1. “Polar amino acid other than K or R at position 423” means the residue can be any polar residue except Lys/Arg. Your dependent claims further reduce it to Q or S (claims 6-8). That creates a clear infringement map: a candidate polypeptide that diverges at position 423, or uses a residue that is polar but is K or R, is outside the literal claim even if it remains 95% identical overall.

Claim set structure (as provided)

Claim	Scope focus	Key literal limitations
1 (independent)	MSC-to-chondrocyte method	95% identity to TABLE/SEQ set + polar residue (not K/R) at pos 423 (vs SEQ ID NO:1) + chondrogenic activity
2	Specific sequence subset	identity to a defined list including SEQ ID NO:30-41 and SEQ ID NO:14-28 (some omissions as written)
3	Even more specific subset	identity to selected SEQ IDs (minor list differences vs claim 2 as written)
4	“Consists of” identity constraint to a subset	identity to listed SEQ IDs with “consists of” phrasing; stronger closure than claim 2/3
5	“Consists of” to another subset	identity to listed SEQ IDs with “consists of” phrasing
6	Residue rule	position 423 is Q
7	Residue rule	position 423 is Q (explicit)
8	Residue rule	position 423 is S
9	Formulation	PEGylated polypeptide
10	Fusion	fusion to HSA, Fc, polyhistidine, GST, thioredoxin, protein A/G, MBP, or fragments
11	Clinical delivery	in vivo; human subject; administered to the joint
12-15	Indication type	arthritis type: OA/trauma/autoimmune; with OA emphasized
16-17	Combination agents	optional additional chondrogenic factors; hyaluronic acid/derivative
18	Combination agents list	calcitonin (oral salmon), SD-6010 (iNOS inhibitor), vitamin D3, collagen hydrolyzate, FGF18, BMP7, rusalatide acetate, ASU, kartogenin, steroid, NSAID
19-20	Procedure bundling	surgical procedure + bone marrow stimulation, ACI, MACI, cartilage replacement

Business implication: the patent’s enforceable sweet spot is narrow at the polypeptide definition layer (95% identity + pos 423 chemistry + chondrogenic function), then broadens downstream with delivery and combination procedure steps.

Where the claim language creates enforceability leverage vs litigation fragility

Leverage: sequence identity + residue gating

95% identity constrains design-arounds to near-neighbors of the claimed sequences.
Position 423 residue constraint provides a “single-point” escape hatch: change that locus and you likely avoid literal infringement if the residue becomes K or R or stops being polar as defined.

Fragility: “chondrogenic activity” and “TABLE 1 / SEQ ID anchored position 423”

Chondrogenic activity is a functional limitation. In litigation, this can devolve into arguments about what assays count, what dosing matters, and whether specific variants still meet the activity threshold.
The meaning of “position 423 … as determined with reference to SEQ ID NO:1” is a common friction point: a candidate manufacturer may argue alignment differences, numbering differences due to insertions/deletions, or frame/processing differences if the polypeptide is post-processed (PEGylation, fusion, truncations). Your dependent claims allow fusions and PEGylation, which can invite disputes about whether “position 423” refers to the unmodified backbone or the final processed construct.

How broad are claims 2-5 compared to claim 1?

Claims 2-5 are not merely “narrow.” They are also compliance maps listing acceptable SEQ IDs. The practical effect is:

Claim 1: you can pick any sequence from TABLE 1 that meets identity and pos 423 constraints, plus chondrogenic activity.
Claims 2-3: list eligible sequences more concretely, changing which design-arounds might still qualify under the broader claim set.
Claims 4-5: “consists of” language increases closure. If the final product includes extra residues beyond the claimed construct boundary, “consists of” can be a tighter literal fence than “comprising.”

What do dependent claims 9-10 do to the infringement surface?

PEGylation (claim 9)

If the core polypeptide is claimed, PEGylation may create an alternative infringing product family if the PEGylated form still falls within the defined polypeptide boundary.
If the polypeptide definition is tied to amino acid sequence identity, the key is whether PEGylation alters the polypeptide sequence (it usually does not) or adds residues (site-specific PEGs generally do not).

Fusions (claim 10)

Fusions to HSA, Fc, GST, thioredoxin, protein A/G, MBP, etc. can widen commercial applicability. For enforcement, the legal question typically becomes whether the “polypeptide” with the required sequence identity and pos 423 property includes the fusion moiety or only the backbone. Since claim 10 states the polypeptide is “fused to” heterologous peptides, the polypeptide may be treated as the fusion construct for identity/positioning purposes unless the patent clarifies that position 423 refers only to the native region.

Business consequence: for competitors, fusions are a known safe path only if they allow robust arguments that the claimed identity/positional requirements apply only to the core and the final construct no longer meets the strict positional mapping.

How claims 11-20 shift from molecule IP to method-of-use IP

Claims 11-20 add in vivo human joint administration and indications and combination regimens. These are often easier to find evidence for (clinic protocols, labeling, investigator brochures) but can be harder to enforce if commercial activity omits procedure steps.

Indication-specific narrowing

Arthritis types: osteoarthritis, trauma arthritis, autoimmune arthritis (claim 14)
osteoarthritis emphasized (claim 15)

Combination therapy list (claims 16-18)

The dependent claims enumerate adjuncts including:

Hyaluronic acid or derivative (claim 17)
Oral salmon calcitonin; SD-6010 (iNOS inhibitor); vitamin D3; collagen hydrolyzate; FGF18; BMP7; rusalatide acetate; avocado soy unsaponifiables (ASU); kartogenin; steroid; NSAID (claim 18)

Critical point: these combination steps can materially narrow the direct infringement pathway. If a competitor uses the polypeptide without HA or without the listed adjuncts, claims 16-18 may not be directly infringed. But the presence of these options can still create a broader “landing zone” for enforcement if real-world regimens combine them.

Procedure bundling (claims 19-20)

Claims cover surgical and cartilage repair workflows:

surgical procedure (claim 19)
bone marrow stimulation, cartilage replacement, ACI, MACI (claim 20)

This is method-of-use scaffolding. In practice, commercial adoption of stem-cell differentiation therapies often comes bundled with ortho interventions. That increases evidence availability but also ties infringement to specific clinical workflows.

What is the patent landscape likely to look like around this claim set (US-focused)?

This landscape analysis depends on whether the patent is a continuation/correction in a known family and whether the enumerated SEQ IDs correspond to:

a known secreted chondrocyte differentiation factor
an engineered version with single-residue changes at pos 423
an Fc-fusion/PEGylated engineered construct
or an MSC-directing scaffold

Without the full specification, claim 1 already signals a typical motif: engineered polypeptide variants of a known protein with an activity-preserving locus mutation, then expanded to delivery formats and clinical regimens for joint diseases.

Competitive threat map (design-around and infringement risk)

Competitor move	How it interacts with the claim constraints
Use a different chondrogenic growth factor (e.g., FGF18/BMP7/kartogenin)	Likely avoids claim 1 unless their polypeptide matches the 95% identity + pos 423 constraint
Use the same backbone but change residue at position 423 to a disallowed residue	Strong design-around against claims 1, 6-8
Use near-identical sequences (95%+) but with different residue at pos 423	Might still avoid literal infringement if pos 423 fails polar-not-K/R test
Use PEGylated or fused version	Could still infringe if the core polypeptide sequence and pos 423 residue remain within constraints
Market as a stand-alone in vitro differentiation protocol rather than in vivo joint administration	Avoids claims 11-20, but not necessarily claim 1 if the method is practiced as claimed
Use same polypeptide but avoid specific combination agents/procedures	Avoids dependent claims 16-20; may still face claim 1 exposure

Litigation posture likely to be centered on

sequence alignment to establish 95% identity
residue mapping for position 423 relative to SEQ ID NO:1
proof of chondrogenic activity
whether competitor constructs fall under “consists of” vs “comprises” closure language (claims 4-5)

Key takeaways

US 10,533,042 claims a precise engineered polypeptide-defined method for MSC-to-chondrocyte differentiation using 95% identity to enumerated SEQ IDs plus a position 423 polar-not-K/R residue rule and chondrogenic activity requirement.
The broadest claim is constrained at the molecule definition layer; downstream claims broaden into in vivo joint administration and combination/procedure bundles, creating multiple evidence anchors but also multiple paths for design-around by changing regimen components.
The highest-leverage infringement questions are (1) sequence identity, (2) residue at pos 423, and (3) whether the competitor’s exact construct qualifies as “the polypeptide” for the identity/positioning requirement in PEGylated or fusion formats.
For competitors, the most efficient escape paths are typically altering the pos 423 residue or avoiding regimens tied to dependent combination/procedure claims, while avoiding literal sequence identity overlap.

FAQs

Is claim 1 limited to a single polypeptide sequence?
No. It covers polypeptides with at least 95% identity to sequences selected from the enumerated TABLE/SEQ set, provided the pos 423 residue rule and chondrogenic activity are met.
What is the most important design-around lever in this patent?
The amino acid at position 423. Claims 6-8 explicitly restrict it to Q or S, and claim 1 restricts it to a polar amino acid other than K or R.
Do claims 9-10 increase or decrease competitive flexibility?
They increase enforcement surface by covering PEGylated and fusion variants. Competitors cannot rely on PEGylation or fusion alone to avoid infringement if the core sequence and pos 423 requirements are unchanged.
Do dependent claims 16-20 make infringement easier or harder?
They can make it easier to find evidence when real clinical practice bundles adjuncts and procedures, but they also make direct infringement more fact-dependent because missing adjuncts/procedure steps may defeat those dependent claims.
If a competitor uses the same MSC differentiation approach in vitro only, does it avoid this patent?
It may avoid claims 11-20 tied to in vivo human joint administration, but claim 1 can still apply if the method of contacting MSCs with the claimed polypeptide is practiced as claimed.

References

[1] United States Patent and Trademark Office. (n.d.). US Patent 10,533,042.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	December 13, 2016	10,533,042	2037-12-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,533,042

Summary for Patent: 10,533,042